Marjolein de Bruijn

Marjolein de Bruijn

Auto-generated profile, based on publicly available information

Marjolein de Bruijn

Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam 1066 CX, Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PVPaula Voabil
Paula Voabil
MBMarjolein de Bruijn
Marjolein de Bruijn
LRLisanne Roelofsen
Lisanne Roelofsen
SHSanne H. Hendriks
Sanne H. Hendriks
SBSimone Brokamp
Simone Brokamp
DTDaniela S. Thommen
Daniela S. Thommen

27 April 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
PKPaulien Kaptein
Paulien Kaptein
CJCelia Jacoberger-Foissac
Celia Jacoberger-Foissac
PDPetros Dimitriadis
Petros Dimitriadis
PVPaula Voabil
Paula Voabil
MBMarjolein de Bruijn
Marjolein de Bruijn
MTMichele W.L. Teng
Michele W.L. Teng
Neoadjuvant immunotherapy with anti-cytotoxic T lymphocyte–associated protein 4 (CTLA4) + anti–programmed cell death protein 1 (PD1) monoclonal antibodies has demonstrated remarkable pathological responses and relapse-free survival in ~80% of patients with clinically detectable stage III melanoma. However, about 20% of the treated patients do not respond. In pretreatment biopsies of patients with melanoma, we found that resistance to neoadjuvant CTLA4 + PD1 blockade was associated with a low CD4/interleukin-2 (IL-2) gene signature. Ex vivo, addition of IL-2 to CTLA4 + PD1 blockade induced T cell activation and deep immunological responses in anti-CTLA4 + anti-PD1–resistant human tumor specimens. In the 4T1.2 breast cancer mouse model of neoadjuvant immunotherapy, triple combination of anti-CTLA4 + anti-PD1 + IL-2 cured almost twice as many mice as compared with dual checkpoint inhibitor therapy. This improved efficacy was due to the expansion of tumor-specific CD8 + T cells and improved proinflammatory cytokine polyfunctionality of both CD4 + and CD8 + T effector cells and regulatory T cells. Depletion studies suggested that CD4 + T cells were critical for priming of CD8 + T cell immunity against 4T1.2 and helped in the expansion of tumor-specific CD8 + T cells early after neoadjuvant triple immunotherapy. Our results suggest that the addition of IL-2 can overcome resistance to neoadjuvant anti-CTLA4 + anti-PD1, providing the rationale for testing this combination as a neoadjuvant therapy in patients with early-stage cancer.

12 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RMRiccardo Mezzadra
Riccardo Mezzadra
MBMarjolein de Bruijn
Marjolein de Bruijn
LJLucas T. Jae
Lucas T. Jae
RGRaquel Gomez-Eerland
Raquel Gomez-Eerland
ADAnja Duursma
Anja Duursma
TSTon N. Schumacher
Ton N. Schumacher
Experimental and clinical observations have highlighted the role of cytotoxic T cells in human tumor control. However, the parameters that control tumor cell sensitivity to T cell attack remain incompletely understood. To identify modulators of tumor cell sensitivity to T cell effector mechanisms, we performed a whole genome haploid screen in HAP1 cells. Selection of tumor cells by exposure to tumor-specific T cells identified components of the interferon-γ (IFN-γ) receptor (IFNGR) signaling pathway, and tumor cell killing by cytotoxic T cells was shown to be in large part mediated by the pro-apoptotic effects of IFN-γ. Notably, we identified schlafen 11 (SLFN11), a known modulator of DNA damage toxicity, as a regulator of tumor cell sensitivity to T cell-secreted IFN-γ. SLFN11 does not influence IFNGR signaling, but couples IFNGR signaling to the induction of the DNA damage response (DDR) in a context dependent fashion. In line with this role of SLFN11, loss of SLFN11 can reduce IFN-γ mediated toxicity. Collectively, our data indicate that SLFN11 can couple IFN-γ exposure of tumor cells to DDR and cellular apoptosis. Future work should reveal the mechanistic basis for the link between IFNGR signaling and DNA damage response, and identify tumor cell types in which SLFN11 contributes to the anti-tumor activity of T cells.